Articles On Noxopharm (ASX:NOX)

The ASX is likely to open steady as Wall Street was closed Iron ore prices have fallen but remain stable September is historically tough for investors   The ASX is likely to open steady on Tuesday, with Wall Street closed for Labor Day an...

ASX ended 10-day winning streak ANZ, Tabcorp dropped after facing regulators Despite a crude price rebound, energy stocks fell   The ASX 200 ended its 10-day winning streak, dipping by 0.04% after a weak session on Wall Street overnight....

Control Bionics to gain US$4,300 reimbursement for its NeuroNode device Noxopharm begins a trial for SOF-SKN, targeting lupus, with results due in 2025 HitIQ signs a two-year deal with Westfield Sports High School   Control Bionics to be...

Biotech company Noxopharm Ltd (ASX:NOX) has announced that the first human trial testing SOF-SKN – a novel drug designed to treat autoimmune diseases such as lupus – will begin in Australia next year, leveraging rebates from the federal gov...

This week’s Bulls N’ Bears Runner of the Week is … LiveHire. Its shares rallied 95.83 per cent on an all-cash takeover bid, while other companies to run hard include Artemis Resources, LTR Pharma and Noxopharm.

ASX gained on Wall Street boost and local earnings results CBA, AGL Energy, and Evolution Mining posted strong earnings ASX’s shares dropped after ASIC lawsuit   The ASX extended its gains by on a busy day of earnings reports, up by 0.3%,...

Australian biotech company Noxopharm (ASX: NOX) has announced encouraging new data regarding the development of its CRO-67 preclinical drug for pancreatic cancer. The results arise from a study that tested CRO-67 in a complex model of human...

Noxopharm’s CRO-67 shows significant tumour reduction The drug effectively targets both cancer and protective barrier cells Pro Medicus’ full-year net profit rises 36.5pc   Noxopharm’s drug overcomes tumour barriers Noxopharm (ASX:NOX) ju...

Shares in Noxopharm (ASX:NOX) jumped nearly 40% in morning trades on Wednesday according to Cboe live pricing as the company announced its experimental drug CRO-67 reduced human pancreatic tumour cells implanted into mice. The company re...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Noxopharm said joining the global alliance means it will connect with other organisations, including CSL and BioNTech, working to progress mRNA and other RNA technologies.

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Noxopharm (ASX:NOX) is scaling up the production of its preclinical SOF-SKN lupus medication to the standards required for upcoming regulatory submissions.

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further inves...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

  Local markets started slow before ripping into an all-time intraday high  10 of 11 sectors higher, benchmark closes 0.50pc up Small Caps led by Motio, Cue Energy and Sierra Rutile   Some strong earnings on the last day of February and...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

The ASX benchmark has closed slightly higher on Monday Energy Sector gains after oil prices rose over the weekend Small caps led Killi Resources, Nyrada and Viridis Mining   The Aussie sharemarket has ended the opening salvo of the week...

ASX set to fall despite a modest rally on Wall Street Microchip stocks fell as Microsoft unveiled its new custom AI chip Janus Henderson says investing in dividend stocks won’t always be a sure thing   Aussie shares are poised to open low...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL   The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

mRNA is set to be the new frontier in vaccines, but has serious side effects including inflammation ASX listed Noxopharm has a program to tackle this problem Stockhead reached out to Stockhead’s CEO, Gisela Mautner   Scientists have been...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

The Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP) for July-September grew by 4.9% compared to the previous year.  At the closing bell, the S&P/ASX 200 was 0.3 per cent higher at 7,077.60...

  Don't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here to register. Whitehaven Coal (ASX:WHC) has been placed in a trading halt following an announcement by BHP that Whitehaven Coal is the prefe...

18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR)…

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

Benchmark ASX index finishes +1% higher ASX Sectors led by Utilities (+4.2%) and all ended higher on the day Funny bunch of small cap winners including MOB, CZR, NGL   The ASX200 doesn’t seem to mind a bit of war on Tuesday, rising very...

This week’s Bulls N’ Bears top ASX runner is… Noxopharm. It skyrocketed 323 per cent to join other impressive runners including Dimerix, Roots Sustainable Agricultural Technologies and Toys“R”Us.

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Benchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains, XEC Emerging Co’s index now down 14% from July highs Fascinating small caps action: led by Dimerix, Bluglass and Experience Co.   The ASX2...

The ASX200 is now at its lowest level in eleven months, closing down .8 of a per cent this afternoon. Across the sectors, it was a sea of red – with only utilities bucking the trend – up nearly .4 of a per cent. Financials dropped 1.5...

It's been another depressing session for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, making it three for three so far this week. After tanking a horrid 1.3% yesterday, the ASX...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Fear continued to grip Wall Street last night, sending all of the United States' major indices backwards. The Dow Jones Industrial Average — an index tracking 30 of the most prominent listed companies in the US — fell 1.29% to 33,003.38 po...

It has been yet another difficult day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 1% to 6,871.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why the...

Australian biotechnology company Noxopharm (ASX: NOX) has been granted orphan drug designation (ODD) status by the US Food and Drug Administration for its CRO-67 preclinical drug candidate to treat pancreatic cancer. The FDA grants the stat...

04 Oct 2023 - A snapshot of the stocks on the move, featuring Noxopharm (ASX:NOX), Redstone Resources (ASX:RDS) and Lake Resources (ASX:LKE).

  Noxopharm (ASX:NOX) announces that the US FDA has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer. Noxopharm CEO Dr Gisela Mautner said, “our pancreatic...

New Zealand's central bank is likely to maintain its current interest rates ahead of a general election, with all surveyed economists expecting no change at 5.5 percent. However, policymakers may emphasize the potential for future rate hike...

ASX to open lower, as markets fall in New York  US 10-year yields continue to threaten 5%, so everyone’s still upset  Noxopharm comes good on FDA AND… So. Much. Lithium. News.   Aussie shares are headed for another early October retreat...

The US FDA has granted Orphan Drug Designation status to Noxopharm's (ASX:NOX) CRO-67 preclinical drug candidate for the treatment of pancreatic cancer.